CorMedix (NYSE:CRMD – Get Rating) and ORIC Pharmaceuticals (NASDAQ:ORIC – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.
Profitability
This table compares CorMedix and ORIC Pharmaceuticals' net margins, return on equity and return on assets.
Get
CorMedix alerts:
| Net Margins | Return on Equity | Return on Assets |
| CorMedix | -25,202.44% | -48.87% | -44.76% |
| ORIC Pharmaceuticals | N/A | -32.11% | -29.50% |
Volatility and Risk
CorMedix has a beta of 2.2, meaning that its stock price is 120% more volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
Institutional & Insider Ownership
33.8% of CorMedix shares are owned by institutional investors. Comparatively, 89.7% of ORIC Pharmaceuticals shares are owned by institutional investors. 2.8% of CorMedix shares are owned by insiders. Comparatively, 6.2% of ORIC Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares CorMedix and ORIC Pharmaceuticals' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| CorMedix | $190,000.00 | 846.00 | -$28.21 million | ($0.79) | -4.95 |
| ORIC Pharmaceuticals | N/A | N/A | -$78.71 million | ($2.15) | -2.06 |
CorMedix has higher revenue and earnings than ORIC Pharmaceuticals. CorMedix is trading at a lower price-to-earnings ratio than ORIC Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings for CorMedix and ORIC Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| CorMedix | 0 | 0 | 0 | 0 | N/A |
| ORIC Pharmaceuticals | 0 | 3 | 2 | 0 | 2.40 |
ORIC Pharmaceuticals has a consensus target price of $22.00, suggesting a potential upside of 397.74%. Given ORIC Pharmaceuticals' higher possible upside, analysts plainly believe ORIC Pharmaceuticals is more favorable than CorMedix.
Summary
ORIC Pharmaceuticals beats CorMedix on 8 of the 12 factors compared between the two stocks.
About CorMedix
(Get Rating)
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
About ORIC Pharmaceuticals
(Get Rating)
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
